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Alcohol consumption is a major risk factor for the burden of disease, and Alcohol Dependence
(AD) is the most important disorder attributable to this behavior. The objective of this study
was to quantify mortality associated with AD and the potential impact of treatment. For the EU
countries, for the age group 15–64 years, mortality attributable to alcohol consumption in
general, to heavy drinking, and to AD were estimated based on the latest data on exposure and
mortality. Potential effects of AD treatment were modeled based on Cochrane and other
systematic reviews of the effectiveness of the best known and most effective interventions. In
the EU 88.9% of men and 82.1% of women aged 15–64 years were current drinkers; and 15.3% of
men and 3.4% of women in this age group were heavy drinkers. AD affected 5.4% of men and
1.5% of women. The net burden caused by alcohol consumption was 1 in 7 deaths in men and
1 in 13 deaths in women. The majority of this burden was due to heavy drinking (77%), and 71%
of this burden was due to AD. Increasing treatment coverage for the most effective treatments
to 40% of all people with AD was estimated to reduce alcohol-attributable mortality by 13% for
men and 9% for women (annually 10,000 male and 1700 female deaths avoided). Increasing
treatment rates for AD was identiﬁed as an important issue for future public health strategies
to reduce alcohol-attributable harm and to complement the current focus of alcohol policy.
& 2012 Elsevier B.V. and ECNP. Open access under CC BY-NC-ND license.NP.
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Alcohol use disorders, commonly deﬁned as comprising
alcohol dependence (AD) and alcohol abuse (American
Psychiatric Association, 1994), are globally one of the most
prevalent mental disorders, affecting an estimated 3.6% of
the population between 15 and 64 years of age worldwide
(men: 6.3%; women 0.9%) (Rehm et al., 2009). There are
marked regional variations in prevalence, with the World
Health Organization’s European region showing the highest
prevalence in this age group (5.5% total; men: 9.1%; women
2.0%). Within the European region, Russia and surrounding
countries have the highest prevalence, but the European
Union (EU) also shows a high prevalence (Rehm et al., 2005;
Wittchen et al., 2011).
The public health impact of alcohol use disorders, as with
most other mental disorders, has been mainly seen as
disabling rather than fatal, especially in comparison to
cardiovascular disorders and cancer (Samokhvalov et al.,
2010; World Health Organization, 2008). The disabling effects
manifest themselves in absenteeism from work, failure to
fulﬁll one’s social roles, and other interpersonal problems
and functional problems in daily life (Ormel et al., 1994;
Samokhvalov et al., 2010). As most of the public health
impact of alcohol use disorders stems from AD (Langlois
et al., 2011; Samokhvalov et al., 2010), we will restrict
ourselves to this disorder.
The underlying evidence for the conclusion that the
consequences of AD are disabling rather than fatal stems
from the Global Burden of Disease (GBD) studies (Lopez
et al., 2006; World Health Organization, 2008). The GBD
estimates with respect to mortality associated with AD in
turn have been based on the review of Harris and Barra-
clough (Harris and Barraclough, 1998), indicating a Standar-
dized Mortality Ratio (SMR) of 1.80 (95% conﬁdence interval
(CI): 1.76–1.84) for men and of 3.84 (95% CI: 3.54–4.15) for
women. In other words, people with AD have a 1.8 or
3.8 fold higher ratio of observed deaths to expected deaths
for men and women respectively, where expected deaths
are calculated based on the age- and sex-comparable
general population. However, the Harris and Barraclough
review is quite out of date, with more than 30 new studies
appearing since 1998 (Roerecke and Rehm, 2012). Also,
most of the more recent estimates of mortality risks
associated with AD have been markedly higher than those
reported in the Harris and Barraclough review, especially
those estimates based on treated samples (for two examples
see: (Campos et al., 2011; Hayes et al., 2011)). Studies on
mortality of AD in general populations showed lower risk
than treatment, but still elevated risk compared to the
general population without AD (Dawson, 2000; Fichter
et al., 2011).
It is the aim of this contribution to look into the mortality
impact of AD in the EU based on the latest available
information on exposure, risk relations and mortality. More
speciﬁcally, we estimate the impact of AD on mortality in
each of the member states of the EU, and aggregate the
results for the EU as a whole. In a second step, we compare
estimates of AD-attributable mortality to estimates of the
impact of alcohol consumption overall and of the impact of
heavy drinking in the EU. The approach to estimate on the
country level and then aggregate is necessary as drinkingcultures vary markedly between regions in Europe, and
sometimes vary from country to country or even within
countries, based on product traditions, drinking patterns,
and social reactions to alcohol (Iontchev, 1998; Popova
et al., 2007; Room, 2010).
AD seems to have a marked effect on mortality, and one
way to reduce this effect could be by treatment. There are
effective treatment options for this condition, leading
either to abstinence, or to a reduction in heavy drinking
days and overall consumption (Magill and Ray, 2009; Ro¨sner
et al., 2010a, 2010b; Smedslund et al., 2011). However, less
than 10% of all people with AD are currently treated in the
EU, which is the lowest treatment coverage of any mental
disorder (Alonso et al., 2004; Rehm et al., 2012). Thus, as a
last step, we estimate the effects of increased treatment
interventions on the associated burden of AD.2. Experimental procedures
2.1. Deﬁnition of population
Population was restricted to the 27 countries of the EU. We
restricted age to 15–64 years, as death certiﬁcates are less reliable
with respect to cause of death in older age (Harteloh et al., 2010),
and especially for the very old (Alp erovitch et al., 2009). Also, the
relative risks for alcohol-attributable causes tend to decrease with
age (Klatsky and Udaltsova, 2007). As a result, the consequences of
consumption, both detrimental and beneﬁcial, tend to be exagger-
ated in the older age groups when age-unspeciﬁc relative risks from
meta-analyses are used as is commonly the case. A second reason to
restrict ourselves to people less than 65 years of age was our aim to
concentrate on premature mortality, as this age threshold has often
been used in the European context to deﬁne premature mortality
(Lapostolle et al., 2008). The under 15 year-olds were excluded
since alcohol-attributable deaths in this age group are very rare,
except as the result of the impact of someone else’s drinking (e.g.,
trafﬁc fatalities caused by drunk drivers).2.2. Deﬁnition of exposure categories
Alcohol consumption status was measured in three categories:
lifetime abstainers, former and current drinkers. For current
drinkers, average alcohol consumption in grams of pure alcohol
per day was used as the main exposure variable.
Heavy drinking was deﬁned as the average daily consumption of
alcohol at or above 3.33 standard drinks for women (40+ g of pure
alcohol) and 5 standard drinks for men (60+ g of pure alcohol). The
heavy drinking categories were taken from the European Medicines
Agency guideline on the development of medicinal products for the
treatment of AD (European Medicines Agency, 2010) based on the
monitoring guide of the World Health Organization (World Health
Organization, 2000; see Web Appendix A—2.1 for additional
details). Alcohol dependence was operationalized by standardized
assessment based on either ICD or DSM (Rehm et al., 2005).
Exposure data for alcohol consumption on a country basis were
obtained from the World Health Organization Regional Ofﬁce for
Europe which was processed by the routines implemented in the
Global Information System on Alcohol and Health (for more details
see Shield et al., 2012b and http://www.who.int/gho/alcohol/en/
index.html). Following the methodology developed for the Com
parative Risk Assessment for alcohol of the GBD 2005/2010 study
(Kehoe et al., 2012; Rehm et al., 2010b), information from general
population surveys was triangulated with adult per capita consump
tion to correct for undercoverage (Rehm et al., 2007).
Impact of AD on mortality burden 91Data on the prevalence of AD per country were taken from Rehm
and colleagues (Rehm et al., 2012). These data are summarised
with sources in Web Appendix A—1.
Data on risk relations for alcohol or heavy drinking as exposure
were obtained from the above-mentioned ongoing GBD Compara-
tive Risk Assessment for alcohol (Rehm et al., 2010a). Data on risk
relations for AD are described below in the modeling strategy.
Data on mortality were obtained from the 2004 update of the
GBD study (World Health Organization, 2008). We relied on these
data rather than on country statistics for reasons of comparability
between countries (Lopez et al., 2006).
2.3. Modeling strategy
2.3.1. Estimating mortality attributable to alcohol
and to heavy drinking
In order to estimate alcohol-attributable mortality, we calculated
the sex-, age and disease-speciﬁc Alcohol-Attributable Fraction
(AAF) for all alcohol-attributable diseases and applied these AAFs
to respective mortality cases as obtained from the 2004 GBD study
(Shield et al., 2012b; World Health Organization, 2008). An AAF
represents the proportion of each cause of death that is attribu-
table to alcohol consumption, on the basis of there being the
counterfactual scenario of no alcohol consumption (i.e., everyone is
a lifetime abstainer; for deﬁnitions see (Benichou, 2001; Walter,
1976, 1980)). Similarly, attributable fractions for heavy drinking
were computed. Overall, the same algorithms as the current GBD
study were used (Kehoe et al., 2012; Rehm et al., 2007, 2010a,
2010b; Shield et al., 2012b).
2.3.2. Estimating mortality attributable to AD
The mortality attributable to AD can be estimated by a similar
methodology in principle as was used for alcohol-attributable
mortality (Walter, 1976, 1980), i.e., by calculating the proportion
of deaths attributable to AD based on prevalence of exposure and
sex- and age-speciﬁc relative risk estimates for AD. In addition, two
subpopulations of people with AD were distinguished based on their
mortality risk: For 20% of the people with AD in any given country, we utilized
the risk relations from Hayes et al. (2011), assuming that 20%
reﬂected the proportion of all people with AD who were in
treatment or with similarly severe dependence (Alonso et al.,
2004; Kohn et al., 2004). For the remaining 80% of the people with AD, we assumed a
relative risk of 2.25 for men and 2.7 for women up to age 44,
and of 2 for men and 2.4 for women aged 45 and older, thus
reﬂecting the average level of severity of untreated AD in the
general population (for men there are three general population
studies of mortality risks, two involving a very long follow-up
period (Murphy et al., 2008; Ojesjo¨ et al., 1998; Vaillant, 1996);
in addition there are several studies without separation of sex
(Dawson, 2000; Fichter et al., 2011)).
2.3.3. Estimating the effect of treatment interventions
The effects of treatment of AD have traditionally been measured as
a downward shift of alcohol consumption (either to abstinence or to
reduced drinking (Barbosa et al., 2010)), or by a decrease in the
relative risk of dying (as a result of reduced and more controlled use
of alcohol (McQueen et al., 2011)). In order to estimate the effects
of treatment interventions on the mortality in a given country, the
drinking population of the country was simulated with a set of
100,000 points, each representing one drinker. The average con-
sumption of each ‘‘drinker’’ was simulated using the known drinkingprevalence distribution for each country. It was assumed that
people with AD in need of treatment would be among the heavier
drinkers in the AD population (men consuming 72 g of pure alcohol
or more per day, and women consuming 48 g of pure alcohol or more
per day). People with AD who were also heavy drinkers were thus
randomly selected from the heavy drinking populations, and the
treatment effects were applied to each of them. We simulated the
effects of treating 10%, 20%, 30% and 40% of all people with AD with
ﬁve different interventions which were selected based on the
seminal review of Hester and Miller (2003), for a detailed summary
of assumptions see Table 1). Each drinker’s risk of dying was then
evaluated in this treated drinking population and the AAFs were
then calculated in the same fashion as described above. Comparing
the newly derived AAFs to the original AAFs allowed us to estimate
the lives saved within one year by a given treatment intervention.
Additional details on the methodology can be found in Web
Appendix A—2.2.
2.3.4. Estimating uncertainty
Uncertainty of the AAFs and the mortality attributable to alcohol
consumption and heavy drinking were computed using Monte Carlo
methods (Ross, 2006). Each parameter of the function was randomly
sampled 40,000 times based on their distribution, and these random
sets of variables were used to calculate the variance of the AAFs
(Gmel et al., 2011b; see Web Appendix A—2.1). The more samples
there are, the more closely the estimated variance approaches the
true variance. The uncertainty of the estimates of mortality
attributable to AD was calculated using derivatives (Gmel et al.,
2011a for a similar methodology). The variance of the estimates for
the intervention is described in Web Appendix A—2.2.
3. Results
The prevalence of alcohol consumption among adults 15–64
years of age was high in the EU: 88.9% of men and 82.1% of
women were current drinkers (total 85.5%), and 9.4% of men
and women combined, quite a large proportion, drank
above the thresholds set for heavy drinking (see above for
deﬁnition: 15.3% of men and 3.4% of women). There are
some regional differences: the average level of alcohol
consumption is highest in the Central and Eastern parts of
the EU (Rehm et al., 2012; Shield et al., 2012b). Regional
differences are more pronounced in patterns of drinking,
especially heavy drinking occasions, which are more detri-
mental in Nordic countries, the Central-East and Eastern
regions, and in the British Isles (Rehm et al., 2012; Shield
et al., 2012b), and less detrimental in Mediterranean
Southern Europe.
The prevalence of AD was estimated to be 5.4% for men
and 1.5% for women (overall 3.5%). Again, there are notable
differences between regions: countries located in Southern
Europe (primarily along the Mediterranean Sea) had the
lowest AD rates, with 0.6% for women and 1.7% for men (see
Web Appendix A—1). These primarily wine drinking coun-
tries not only have had the lowest level of average
consumption, but consistently have displayed the least
detrimental drinking patterns in the EU and even globally
(Rehm et al., 2003, 2004). As both average level of
consumption and frequency of heavy drinking occasions
have been linked to AD (Caetano et al., 1997; Dawson
et al., 2008), it is no surprise that the Southern European
countries exhibited the lowest prevalence rates of AD.
However, other possible reasons for these observed AD
prevalence rates are discussed below.
Table 1 Overview of assumptions for modeling interventions.
Interventions Main results (effects assumed to be stable for
1 year)
Risk relations Source
Motivational Interviewing (MI) and
Cognitive Behavioral Therapy (CBT)
1
For MI, an average drop of 15.8 g of pure
alcohol per day was assumed (measured against
no intervention; 95% CI from 9.6 g to 21.8 g
of pure alcohol). The effect after one year was
very small and not signiﬁcant (average: 1.2 g of
pure alcohol reduction per day), the average
effect over the year was a 3.2 g reduction of
pure alcohol per day (95% CI: 1.2 g to 5.2 g
of pure alcohol per day).For CBT, almost the
same effect was found in studies with a no-
treatment control as the comparison condition
(15.9 g of pure alcohol per day). In addition,
Project MATCH did not ﬁnd any signiﬁcant
differences (Project MATCH Research Group,
1997) between MI and CBT.We modeled the
results based on a drop of15.8 g per day over
the year.
The usual dose-dependent risk relations
between average consumption of alcohol
and disease outcomes were used,
multiplied by 2 to account for the overall
higher mortality risk of people with AD
(Harris & Barraclough, 1998). For injury,
the RR from Harris & Barraclough, 1998
was used for AD and the RR from Corrao
et al. (2004) was used for non-dependent
people.
MI: Smedslund et al. (2011) and CBT:
Magill & Ray, (2009)
Motivational Interviewing and
Cognitive Behavioral Therapy 2
An average drop of 21.8 g of pure alcohol per
day was assumed as the upper limit of the CI for
MI/CBT (see above). We assumed proportional
CIs compared to the ﬁrst MI/CBT scenario.
Smedslund et al. (2011)
Brief Intervention (BI) 1 An average drop of 13.5 g of pure alcohol per
day with a 95% CI from 2.7 g to 24.5 g of
pure alcohol.
McQueen et al. (2011) and Room et al.
(2005)
Brief Intervention 2 An average reduction of the RR for mortality by
0.6 (95% CI: from 0.40 to 0.91). This scenario
represents the ‘‘best case’’ for BI, as
hospitalization is linked to mortality, and AD
plays an important role in mediating and
moderating premature mortality (e.g. De
Lorenze et al., 2011; O’Brien et al., 2007).
However, similar effects were obtained in an
meta-analyses on all BIs (Cuijpers et al., 2004).
McQueen et al. (2011)
Pharmacological therapy (for
simulation, the effects of
Randomized Controlled Trials of
acamprosate and opioid antagonist
treatment were combined)
For 55.0% of the patient population there was a
reduction in drinking of 13% on average; for
18.1% of the patient population a reduction in
drinking of 50%; and for 26.8% of the population
abstinence resulted.
Pooled estimates of two reviews of Ro¨sner
et al. (2010a). For this simulation we are
concerned about the differences in
consumption between baseline and follow-
up in the group receiving medications
only.
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Impact of AD on mortality burden 93Nordic countries with overall relatively low adult per
capita consumption, such as Sweden, have a proportionally
much higher percentage of AD. The Central East and Eastern
European countries, and in particular the Baltic countries,
have the highest AD prevalence, stemming primarily from the
combination of high overall consumption and detrimental
drinking patterns, including, but not limited to, heavy binge
drinking (see Rehm et al., 2005 for further explanation).
Figure 1 summarizes these different mortality burdens for
the EU (again for the population aged 15–64 years): the overall
mortality burden from alcohol consumption (only the detri-
mental effects on mortality without considering any beneﬁcial
effects of moderate drinking on diabetes (Baliunas et al., 2009)
and ischemic disease (Puddey et al., 1999; Rehm and Roerecke,
2011)); the net burden, calculated by subtracting the beneﬁcial
effects from the detrimental effects; the burden of heavy
drinking using the European Medicines Agency risk categories of
40+ g of pure alcohol for women and 60+ g of pure alcohol for
men described above; and the mortality burden due to AD.
Overall, alcohol consumption contributes greatly to mor-
tality. Based on the net burden, 1 in 7 deaths in men and
1 in 13 deaths in women in the EU are estimated to be
caused by alcohol consumption. As can be seen clearly, most
of the mortality due to alcohol consumption stems from
heavy drinking (about 77% of the net burden, 67% of the
overall burden). AD comprises 71% of the net burden and
62% of all harmful alcohol-attributable burden. In other
words, the majority of alcohol-attributable burden is due to
AD, presumably by means of heavy drinking.
In the EU as a whole, and in nearly every country
individually (detailed results available from the authors but
not shown), pharmacotherapy is the most effective treat-
ment, closely followed by brief interventions in the hospital.
This order of effectiveness of treatment is reversed if only
men are considered. The other three treatment scenarios
show signiﬁcantly less effectiveness in reducing mortality.
See Web Appendices A—3 and 4.
Increasing treatment coverage to 40% of all people with AD
could lead to a reduced burden of alcohol-attributable
mortality of about 13% for men and 9% for women. This
represents a little less than 12,000 lives saved in the EU within
12 months (10,000 men and 1700 women). Moreover, this
analysis only considers diseases where alcohol has only a direct
effect within one year; i.e., it excludes latent effects, such asAlcohol-attributable Alcohol-attributable(net)
Men 16.1% 13.9%
Women 8.5% 7.7%
Total 13.6% 11.8%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
Figure 1 Proportion of mortality attributable to alcohol cothe effects of alcohol on cancers (International Agency for
Research on Cancer, 2010). It can be hypothesised that the
number of deaths avoided would be signiﬁcantly higher in the
longer term. Although ﬁve times more deaths would be
avoided in men compared to women (see Figures 2 and 3),
this apparent gap is put into perspective when looking at the
proportion of alcohol-related deaths avoided, which is much
more similar between the sexes.4. Discussion
We have shown that alcohol consumption is the cause of a
large premature mortality burden in the EU, that the
majority of this burden seems to be due to AD, and that
more than 10% of this burden could potentially be removed
by increasing treatment capacity and coverage for AD.
Before we discuss implications, the potential limitations
of the key results should be examined. With respect to the
mortality caused by alcohol consumption and heavy drinking
in general, our results conﬁrm the results of the past GBD
risk assessments (Rehm et al., 2009; World Health
Organization, 2009), but, of course, the same limitations
mentioned there apply here. Bias may be introduced by the
modeling of exposure with the triangulation of surveys and
adult per capita consumption including unrecorded con-
sumption where 80% of the adult per capita consumption
was assumed to be consumed (Rehm et al., 2010b). Unrec-
orded consumption, by its very nature, is hard to estimate,
and these estimates contain measurement error (World
Health Organization, 2011). Finally, the risk estimates taken
from the meta-analyses may not apply to all EU countries,
especially with respect to injury where the risk may be
dependent on societal and socio-technical contexts. With
respect to the triangulation, various sensitivity analyses
show that the burden remains substantial under different
methodologies (Rehm et al., 2006; Rey et al., 2010; Shield
et al., 2012a). Unrecorded consumption is less important in
Europe, where only 16% of the overall consumption falls into
this category (Shield et al., 2012b), and, thus, its impact on
the overall results is not signiﬁcant. Finally, most of the
underlying studies in the meta-analyses used are from the
EU or from high income countries with similar conditions as
the EU, so that the relative risks seem to be comparable.Heavy drinking Alcohol dependence
11.1% 10.7%
5.3% 3.7%
9.2% 8.4%
Men Women Total
nsumption and AD for the EU in 2004; 15–64 year olds.
Figure 2 Number of deaths avoided over one year in men by treatment for AD in the EU in 2004 by ﬁve different treatment
modalities.
Figure 3 Number of deaths avoided over one year in women by treatment for AD in the EU in 2004 by ﬁve different treatment
modalities.
J. Rehm et al.94Thus, despite these limitations, the overall conclusion that
alcohol consumption is responsible for a large degree of
premature mortality seems to be justiﬁed.
With respect to the impact of AD, the above conclusions
rely on the underlying assumptions, i.e., the validity of the
prevalence data and the validity of the relative risks. With
respect to prevalence, it should be mentioned that there
may be additional cultural factors which explain the differ-
ences between regions. While alcohol consumption is deeply
culturally embedded in Southern Europe, alcohol problems
and dependence are tabooed in this region, and, thus, these
countries may also have a higher tendency to deny depen-
dence symptoms for reasons of stigma (Room and Ma¨kela¨,
2000). In the rest of Europe, and especially in the Nordic
countries and Central-East and Eastern European countries,
where AD prevalence is notably higher (see Web Appendix
A—1), drinking to intoxication and showing its effects aremuch less of a taboo. As a result, there may be less denial of
AD symptoms explaining the relatively higher prevalence.
While there have been problems with measuring the
prevalence of AD in the general population of the different
countries, there are sufﬁcient, well-conducted studies to
indicate that the estimated overall prevalence of AD of about
3.5% is not an overestimate for Europe. However, some of the
single country prevalence estimates may be under- or over-
estimated. The overall estimate for Europe in our study is
also quite close to other estimates for Europe based on
different methodologies (Rehm et al., 2005; Wittchen et al.,
2011) as well as to estimates from other high income
countries such as the US (3.8% cf. Hasin et al., 2007).
The second underlying assumption concerns the validity
of the relative risks. The mortality risks used above depend
on the pooled estimates for general population studies and
the use of one of the largest recent studies for the
Impact of AD on mortality burden 95treatment samples. Methodologically rigorous meta-
analyses are necessary to quantify the risks for both the
general population and for treatment samples. However,
while such formal analyses may result in slightly different
estimates, the overall conclusion appears to be valid.
Finally, with respect to the potential impact of treatment,
while we used the most rigorously controlled results mainly
from Cochrane reviews, there is always the question to what
degree such studies can be generalized into everyday
practice (Carroll and Rounsaville, 2007; Hollon, 1996;
Nathan et al., 2000). This discussion is usually subsumed
under the headings of ‘‘efﬁcacy’’ versus ‘‘effectiveness’’
(Streiner, 2002). Randomised clinical trials have comprehen-
sive exclusion criteria, often excluding co-morbidities which
are typical for people with AD who are seeking treatment
(Blanco et al., 2008). There are also social characteristics
which have been shown to differ between community
samples of people with AD and participants in randomised
clinical trials (Grant et al., 2007). As our simulation study in
some scenarios included up to 40% of all people with AD in
the general population, these above-noted differences may
become relevant. However, it is hard to predict the direction
of the bias. We have clear examples of treatment where
effectiveness was better than efﬁcacy, such as in modern
methods of treating depression, as well as for the opposite
case where efﬁcacy was better than effectiveness.
Overall, we modeled interventions based on literature
which was not exclusively on people with AD, but included
problem drinkers as well. Many of the underlying trials did
not formally measure AD. Assuming the same effect size for
AD, treatment seems justiﬁed, as motivational interviewing
and cognitive behavioral therapy are widely used in AD
treatment with good effects (Hester & Miller 2003;
Morgenstern et al., 2001). Brief interventions are usually
used for problem drinkers or mild dependence only. We
included brief interventions only in hospital settings, as a
best case scenario, where the effect on mortality had been
assessed in a situation where patients experience higher risk
due to other health conditions. If alcohol consumption is
reduced in such a situation, the effects are more immedi-
ate. On the other hand, the effects of pharmacotherapy,
which overall was found most effective, were mainly tested
in people with more severe dependence.
An important question is the feasibility of treating with
pharmacotherapy 40% of people with AD, and we have very
little experience with respect to pharmacological AD treat-
ment in the community. Currently, pharmacological treat-
ment is used only in a minority of treatment situations
in the EU (Alonso et al., 2004), and most often not in
community or general practitioner settings, but in specia-
lised treatment centers. Studies examining the applicability
of pharmacological approaches in non-specialised settings
should be a priority for future research.
Overall, increasing treatment availability was shown to
have the potential for increasing public health in Europe. In
fact, the order of magnitude of potential gains in mortality
shown above is comparable to potential gains from other
interventions (Rehm et al., 2011) usually recommended as
best policies to reduce alcohol-attributable harms and to
increase public health (World Health Organization, 2010)
for Europe (see the recently adopted WHO action plan for
2012–2020 to reduce the harmful use of alcohol in theEuropean region http://www.euro.who.int/__data/assets/
pdf_ﬁle/0006/147732/wd13E_Alcohol_111372.pdf). However,
increasing treatment availability should not replace current
alcohol policies in Europe, but rather should be implemented
in addition to proven, cost-effective alcohol policy measures
such as increasing price, banning advertising, or restricting
availability of alcoholic beverages (Anderson et al., 2009;
Chisholm et al., 2004), as different measures are directed
at different sub-populations. Prevention and treatment are
both important to reduce the alcohol-attributable burden
in Europe.
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